Skip to main content
Caplight Logo









i2O Therapeutics

i2O Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://i2obio.com/

Last Round

Series A

Aug 28, 2023

Total Funding Raised

$50.6M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

i2O Therapeutics is a biotechnology company that develops oral formulations of therapies traditionally limited to injections using proprietary ionic liquid technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

oral delivery platformdrug delivery technologybiologicsoral biologicsionic liquidpeptide deliverynanobody deliveryoral drug deliverypill for biologicsmacromolecule deliverybiotech licensingdrug formulationoral bioavailabilitypharma partnershipdrug delivery startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

i2O Therapeutics Comparables

Compare i2O Therapeutics with similar companies based on industry and business-model similarity.

i2O Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vivtex
91%
Cyprumed GmbH
86%
Rani Therapeutics
82%

i2O Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AAug 28, 2023
SeedDec 3, 2020
SeedApr 9, 2020

Key People

Founding team and executive leadership

Kurt Graves

Chairman, President CEO

Executive Team

i2O Therapeutics Investors

Notable investors and investment history

i2O Therapeutics investors
InvestorRounds
Cerity Partners VenturesSeries A
HM Venture PartnersSeries A
Colorcon VenturesSeries A, Seed
Sanofi VenturesSeries A, Seed
JDRFSeed
7G BioventuresSeries A
Hikma VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 29, 2026

    Monthly visitors increased 255% MoM, from 419 to 1.5K.

  • Apr 20, 2026

    Monthly visitors grew 143% MoM, reaching 657.

i2O Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

i2O Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about i2O Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range3
Year Founded2019
Last FundingAug 28, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?